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Expression profiles of thioredoxin family proteins in human lung cancer tissue: correlation
with proliferation and differentiation
Aims: Lung cancer is one of the most common causes
of cancer lethality worldwide. Despite recent progress,
long-term survival remains poor. The aim of this study
was to explore the expression pattern of the thioredoxin
superfamily of proteins as potential new diagnostic
and ⁄ or predictive markers.
Methods and results: The expression of thioredoxin 1
(Trx1), thioredoxin reductase 1 (TrxR1), the isoforms
TrxR1-v.2,3,5, glutaredoxin 1 (Grx1) and glutaredoxin
2 (Grx2) was examined by immunohistochemistry on
paraffin-embedded sections from 42 cases of non-small
cell lung cancer patients. Additional cases of lung
cancer from tissue microarray were examined and the
immunoreactivity was compared. All proteins except
TrxR1 showed a significant correlation with the degree
of differentiation in adenocarcinoma. Trx1 and TrxR1-
v.2,3,5 also showed a significant correlation with
differentiation in squamous carcinoma. Furthermore,
Grx1 and Grx2 showed a clear inverse correlation with
proliferation. The proliferation rate was further analy-
sed in vitro in stably transfected Grx2 overproducing
cells, showing that the proliferative effect of Grx2 is
strictly dependent on subcellular localization.
Conclusions: The thioredoxin family of proteins is
important for growth and differentiation of lung cancer
cells. The correlation with differentiation and prolifer-
ation of these enzymes makes them promising predic-
tive ⁄ diagnostic markers.
Keywords: diagnostic markers, differentiation, lung cancer, proliferation, thioredoxin system
Abbreviations: EGFR, epidermal growth factor receptor; GR, glutathione reductase; Grx, glutaredoxin;
GSH, glutathione; mGrx2a, mitochondrial Grx2a; NADPH, nicotinamide adenine dinucleotide phosphate;
PCR, polymerase chain reaction; TMA, tissue microarray; Trx, thioredoxin; TrxR, thioredoxin reductase;
TTF-1, thyroid transcription factor-1
Introduction
Lung cancer is the most common cause of cancer
lethality.1 The resistance to chemotherapy can be both
primary and secondary. However, most tumour types
acquire secondary drug resistance. Today the 5-year
survival rate is no better than 15%. The molecular
mechanisms behind the resistance to chemotherapy of
these tumours are known to a limited extent. However,
there is clear evidence that it is linked to increased
defence against free radicals, and several studies have
further shown strong indications that cellular redox
systems are involved.
The thioredoxin and glutaredoxin systems are two
multifunctional redox active protein disulphide reduc-
tase systems, widely distributed in nature.2,3 The
thioredoxin system comprises thioredoxin (Trx),
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thioredoxin reductase (TrxR) and nicotinamide adenine
dinucleotide phosphate (NADPH), whereas the glutare-
doxin system consists of NADPH, glutathione reductase
(GR), glutathione (GSH) and glutaredoxin (Grx). Both
redox systems are involved in several important bio-
logical functions such as apoptosis, defence against
oxidative stress, synthesis of DNA, thiol redox control of
enzymes, as well as regulation of receptors and tran-
scription factors.4 All redox proteins belonging to the
thioredoxin and glutaredoxin systems exist as iso-
enzymes, where Trx1, TrxR1 and Grx1 are mainly
cytosolic, and Trx2, TrxR2 and Grx2 predominantly
localize to the mitochondria.5,6 Several of these proteins
are also further subjected to alternative splicing, gener-
ating different protein variants from the same gene.
TrxR1 can result in five protein variants,7 TrxR1-v1 to
TrxR1-v5, and Grx2 is believed to give rise to three forms,
Grx2a–c.8
Numerous reports have implicated the thioredoxin
system in tumour growth and resistance.9 It has, for
example, been shown that TrxR1 deficiency can reverse
the morphology and tumorigenicity of lung carcinoma
cells.10 Using TrxR1 knock down cells, it has also been
suggested that TrxR1 is essential for tumour growth in
mice. In squamous lung cancer the expression of Trx1
and TrxR1 are elevated, especially in highly differenti-
ated cells.11,12 High levels of Trx1 have further been
linked to chemotherapeutic resistance.13 It has therefore
been suggested that TrxR and Trx are prime targets for
cancer therapy.14,15 TrxR is known to be a drug target
for several cytostatic agents through nucleophilic
attacks on the active site.9,16 Recently, TrxR has also
been shown to be a target for the chemopreventive
agents Resveratrol17 and Motexafin gadolinium.18
Flavinoids have also been shown to target TrxR.19
The differentiation of tumour cells is generally
directly correlated to prognosis. The involvement of
antioxidant proteins in the control of differentiation has
previously been reported.20–22
Taken together, there is increasing evidence of, and
understanding of the implications of thioredoxin and
glutaredoxin systems’ involvement in tumour develop-
ment and resistance. We aimed to map Grx1, Grx2,
Trx1, TrxR1 and its isoforms in human lung cancer,
and thus explore the prognostic and diagnostic
potential of these proteins.
Materials and methods
clinical material
Paraffin blocks of 42 tumours from patients with lung
cancer (adenocarcinoma n = 24, large cell carcinoma
n = 6, and squamous cell carcinoma n = 12) were
randomly selected from the archive at the Laboratory
for Clinical Pathology, Karolinska University Hospital
in Huddinge, Sweden, following approval from the
regional ethics committee. Tissue microarray (TMA)
sections (1 mm in diameter) including tissue material
from 127 patients with lung cancer (adenocarcinoma
n = 90, large cell carcinoma n = 6, squamous cell
carcinoma n = 20, and small cell carcinoma n = 11)
were kindly provided by M. Barbareschi (Department of
Pathology, S. Chiara General Hospital, Trento, Italy).
The TMA samples were completely anonymous; indi-
vidual samples could not be tracked and no informa-
tion was provided concerning the identities of the
patients.
The tumours were graded according to the American
Joint Committee on Cancer,23 where grade I represents
highly, grade II moderately and grade III poorly
differentiated as assessed by nuclear polymorphism,
degree of anisokariosis, architectural disorder, gland
formation and mucus production. Large cell carcinomas
were all assessed as poorly differentiated (grade III).
preparation of paraffin-embedded cells
Grx2-overexpressing HeLa cell lines were cultured in
RPMI 1640 medium at 37C and 5% CO2. Cells were
collected with a cell scraper and centrifuged at 300 g
for 7 min. The supernatant was discarded and the
pellet resuspended in 200 ll of human blood plasma.
Fibri-prest2 (0.5 ml; Diagnostica, Stago, Asnieres,
France) was added and incubated at room temperature
for 5 min. The resulting pellet was then fixed in 4%
formalin overnight, thereafter embedded in paraffin
and cut in 3 lm thick sections and stained for Mib-1
(see below).
immunohistochemistry
For immunohistochemistry, 3-lm tissue sections were
deparaffinized in xylol and rehydrated in decreasing
concentrations of ethanol. The tissue sections were
heated in a microwave oven for 10 min in 0.01 m
citrate buffer, pH 6.0, for antigen retrieval. The auto-
matic Dako TechMate 500 was used for staining (Dako,
Glostrup, Denmark). Tissue slides were stained with
primary antibodies against TrxR1 (Upstate, Billerica,
MA, USA), 1:1000; TrxR1-v.2,3,5,22 1:250; Grx1
(IMCO, Stockholm, Sweden), 1:50; Grx2 (Histo-Line,
Seoul, Korea), 1:50; and Trx1 (IMCO), 1:100, diluted in
ChemMate antibody diluent (Dako), for 25 min at
room temperature. For visualization Dako ChemMate
Detection kit Peroxidase ⁄ Diaminobenzidine (Dako) was
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used. The sections were counterstained with haemat-
oxylin. The specificity of the primary antibody reaction
was confirmed by pre-incubation for 1 h at 37C of the
antibody with the specific antigen before staining. In
addition to the redox enzymes, the sections were
stained for the proliferation marker Mib-1 (equivalent
to Ki67) (stained by the accredited laboratory facility at
Karolinska University Hospital).
mathematical determination of
immunoreactivity
Using the Hue Saturation and Intensity mathematical
model,24 the saturation of a given colour was used to
compare different degrees of positivity of immuno-
histochemically stained sections. The method consisted
of the following steps: selection of the range of the
colour (here, brown, in the range 30–45) and
measurement of the saturation of the hue in the
tumour cells relative to surrounding non-tumorous
tissue in the same section [scale 0–1, 0, completely
negative, 1, weak positivity (saturation between 0.01
and 0.33), 2, moderate positivity (saturation between
0.34 and 0.66), 3, strong positivity (saturation
between 0.67 and 1)]. The image analysis software
used is described by Cunnea et al.25 Results were
analysed using the STATISTICA software (StatSoft Inc.,
Tulsa, OK, USA).
dna extraction from paraffin-embedded
material
Genomic DNA was purified from paraffin-embedded
human lung tumour material (the TMA cases were not
examined). Sections were deparaffinized according to
standard protocol, scraped into an Eppendorf tube and
purified using the QIAamp DNA Micro kit (Qiagen,
Solna, Sweden) according to the manufacturer’s
protocol.
nested polymerase chain reaction and
sequencing
Nested polymerase chain reaction (PCR) amplifications
were performed with primers amplifying parts of exon
18, 19 and 21 of epidermal growth factor receptor
(EGFR) as described.26 The PCR mixture contained
sample DNA, 0.2 lm of each primer, 0.2 mm of each
deoxyribonucleotide triphosphate, 2.5 units of Taq
DNA polymerase (Qiagen), 1· Q solution (Qiagen)
and 1· PCR buffer containing 1.5 mm MgCl2. The
following PCR programme was used – initial denatur-
ation at 95C for 4 min, followed by 35 cycles as
follows: 94C for 30 s, 51C for 30 s, and 72C for
60 s. The final extension was at 72C for 10 min. For
purification of the PCR products the MiniElute PCR
purification kit was used (Qiagen). The size of the
products was confirmed by electrophoresis on a 1%
agarose gel before DNA sequence analysis (Cybergene
AB, Stockholm, Sweden).
statistical evaluation
For statistical analysis Wilcoxon matched pairs test was
used and correlation analysis was performed by using
the Spearman rank correlation test with a significance
level at P < 0.05.
Results
immunohistochemical characterization
To investigate the expression pattern of members of the
thioredoxin superfamily, 42 cases of variously differ-
entiated lung cancer were selected from archived
material. A summary of patient characteristic is
presented in Table 1. Using antibodies for Trx1, TrxR1,
TrxR1-v.2,3,5, Grx1 and Grx2, we determined the
expression patterns for each protein in all sections. All
of the above examined proteins were localized in the
cytosol except for Grx2, which was predominantly
localized in the mitochondria. To measure and compare
the different degrees of positivity of the expression
patterns of the thioredoxin family proteins, we based
Table 1. Characteristics of 42 lung cancer patients
Patient characteristics
Total
(n = 42)
Women
(n = 26)
Men
(n = 16)
Age
Mean 66 65 68
Min. 31 31 57
Max. 78 78 78
Histology
Adenocarcinoma 24 19 5
Squamous carcinoma 12 5 7
Large cell carcinoma 6 2 4
Smoking
Smoker 26 18 8
Ex-smoker 14 6 8
Never smoked 2 2 0
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the evaluation on the hue saturation of the immuno-
reactivity of the tumour tissue compared with that
of the non-tumour tissue of the same section. The
expression levels of all proteins except for TrxR1 were
significantly elevated in the tumour area of the section.
A representative figure is shown for Trx1, illustrating
the immunoreactivity in adenocarcinoma with differ-
ent degrees of differentiation (Figure 1).
correlation of intensity of immunoreactivity
of redox enzymes and grading
As seen in Figure 2, all redox proteins showed a higher
intensity of reactivity in the adenocarcinoma area
compared with the surrounding non-neoplastic tissue
from the same section. Apart from the increased
expression of the enzymes examined in the tumour
sections, Trx1, TrxR1-v.2,3,5, Grx1 and Grx2, all
showed a significant correlation with the degree of
differentiation in the adenocarcinoma cases (Fig-
ure 2A). The highly differentiated tumours resulted in
the maximum intensity of immunoreactivity of the
redox proteins. To confirm further the expression
patterns and correlation with differentiation, an addi-
tional 127 cases were analysed from TMA. The TMA
supported these findings with an almost identical
pattern (Figure 2B). A combined summary of all data
for the adenocarcinomas is presented in Figure 2C. Of
note is the staining against TrxR1-v.2,3,5, which had a
much stronger correlation with differentiation and was
not seen for the total TrxR1.
The results from the squamous, large cell and small
cell carcinoma cases are listed in Table 2. The general
expression pattern showed a lower immunoreactivity
in these sections compared with adenocarcinoma,
probably due to higher grading. Significant differences
compared with non-neoplastic tissue are shown in
Table 2. A significant correlation with differentiation in
the squamous cell carcinomas was observed only for
TrxR1-v.2,3,5 (P < 0.05) and Trx1, which had a high
degree of correlation (P < 0.001). No correlation test
could be performed on large cell and small cell
carcinomas, since all of them were graded as poorly
differentiated (grade 3).
proliferation and intensity of
immunoreactivity of redox proteins
The 42 sections were stained with the proliferation
marker Mib-1. Correlation of Mib-1 with the redox
enzymes displayed a significant correlation with both
Grx1 and Grx2 (P < 0.01 and 0.001, respectively)
(Figure 3), where higher proliferation resulted in
decreased levels of these enzymes.
proliferation index in grx2-overexpress ing
cells
Cells stably overexpressing Grx2 were used to verify the
results from immunohistochemistry, showing a high
degree of correlation between Grx2 and the prolifera-
tion rate. Control mock transfected cells, cells over-
A B
D E
C
Figure 1. Immunohistochemistry of human
lung cancer sections for Trx1. A, Adenocar-
cinoma, grade 1. B, Adenocarcinoma, grade
2. C, Adenocarcinoma, grade 3. D, Squa-
mous carcinoma grade 2. E, Squamous
carcinoma grade 3.
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expressing mitochondrial Grx2a (mGrx2a), and cells
overexpressing Grx2a lacking the mitochondrial trans-
location signal, resulting in elevated cytosolic levels of
Grx2a, were compared (Figure 4). The results show
that there were no significant differences between the
control cells (42% positivity) and cells overexpressing
the cytosolic form of Grx2a (50% positivity). However,
the mGrx2a showed a marked increase in proliferation
of >90% positivity, indicating that cytosolic Grx2a is
overexpressed in lung cancer.
egfr
Mutational analysis was performed by PCR followed by
sequencing in order to examine potential mutations in
the EGFR exons 18, 19 and 21, all known to have
specific alterations connected to drug resistance in lung
cancer. The PCR and sequence determination con-
firmed that no mutations were present in the sections
examined (data not shown).
Discussion
In recent decades substantial progress has been
achieved in the diagnosis and treatment of several
human cancers. However, the result for lung cancer
remains poor and, as a consequence, lung cancer is
now the leading cause of cancer death worldwide,
although lung cancer is not the predominant malig-
nancy.1 There is clearly a need for improved knowledge
about lung cancer at all levels, from basic science to
clinical investigations.
This study has described the expression patterns of
thioredoxin family proteins in a large clinical sample of
human lung tumours. There was a clear inverse
correlation between the intensity of immunoreactivity
of all proteins except for TrxR1 and tumour grade in
adenocarcinoma cases. The strongest intensity was
observed in highly differentiated tumours, whereas the
weakest was observed in poorly differentiated tumours.
This negative correlation between grade and immuno-
reactivity is supported by previous data suggesting a
correlation between epithelial phenotype and expression
of Trx and TrxR.21,27 Neither Trx1 nor TrxR1 ⁄ TrxR1-
v2,3,5 correlated with proliferation index in our mate-
rial, although several other studies have suggested that
high levels of Trx1 in other tumour cells are associated
with a more aggressive phenotype with increased
proliferation and decreased apoptosis.28–30 This demon-
strates the complexity and diversity in the regulation of
proliferation in various tumour cells.
Immunohistochemistry is widely used in the diag-
nosis of primary and metastatic tumours of the lung.31
However, there is no single prognostic or diagnostic
marker available. Thyroid transcription factor-1 (TTF-1)
is highly specific for lung histogenesis and is used to
detect lung metastasis throughout the body and also to
distinguish between primary and secondary tumours in
the lung. However, TTF-1 expression is not primarily
used to correlate differentiation and grade. During lung
carcinogenesis several immunohistochemical markers
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Figure 2. Correlation of the different grades in adenocarcinoma
tissue with the intensity of immunoreactivity of the redox proteins
(Grx1, Grx2, Trx1, TrxR1, TrxR1-v.2,3,5). The staining intensity was
calculated by comparison with the non-neoplastic tissue within the
section (set to 0). A, Results from immunohistochemistry of 24 tissue
sections. B, Results from immunohistochemistry staining of tissue
microarray (TMA) material of 90 cases. C, Combined results from
tissue sections and TMA material. Protein expression was correlated
with tumour grade using the Spearman rank correlation test. Stars
denote statistical significance of expression in the tumour material
correlated with grade: *P < 0.05; **P < 0.01; ***P < 0.001.
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are often observed, including Ki67, cyclin D1, hTERT
and survivin.32 The thioredoxin family proteins are
also important in the carcinogenic process and are
suggested to be part of the resistant phenotype
expressed by tumour precursors and overt cancers.33,34
In a previous study Trx and TrxR were shown to
correlate inversely with grade, but the predominant
tumour investigated by these authors was squamous
carcinoma.11 In the present study, the predominant
tumour type was adenocarcinoma and the inverse
correlation was most pronounced in this phenotype.
Furthermore, we found the strongest correlation
between grade and intensity of immunoreactivity with
the antibody against the isoforms TrxR1-v2,3,5, indi-
cating that one or more of these isoforms has different
effects than classical TrxR1. This in turn suggests that
one of the isoforms has a tumorigenic function and
thus might be used as a prognostic tool. Cancer-specific
alternative splicing has been shown for >300 genes,
although the divergent patterns of protein variants are
largely unknown.35
Table 2. Intensity of
immunoreactivity of redox
proteins in lung cancer
compared with surrounding
non-neoplastic tissue
Protein Squamous G2 Squamous G3 LC G3 SCLC G3
Grx1 2.43 ± 0.53* 0.8 ± 0.45 1.83 ± 0.98* 0
Grx2 0.50 ± 0.52* 0 0.67 ± 0.82 1.00 ± 0
Trx1 1.71 ± 0.78*** 0.83 ± 0.98 2.08 ± 0.51** 1.30 ± 0.48**
TrxR1 1.58 ± 0.77*** 1.2 ± 0.92* 1.64 ± 1.21* 1.80 ± 0.42**
TrxR1-v.2,3,5 1.25 ± 1.02*** 0.8 ± 0.79* 1.67 ± 0.71** 1.29 ± 0.49*
For statistical analysis Wilcoxon matched pairs test was used (*P < 0.05; **P < 0.01;
***P < 0.001).
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Figure 3. Grx1 and Grx2 expression in adenocarcinoma correlated
with proliferation rate. Percentage of Mib-1 immunoreactivity in 24
tissue sections was compared with expression of Grx1 (A) and Grx2
(B). Scale of antibody positivity: 0, completely negative; 1, weak
positivity; 2, moderate positivity; 3, strong positivity. Grx1 and Grx2
showed a significant (P < 0.01 and 0.001, respectively) negative
correlation with proliferation, as measured by Mib-1 reactivity.
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Figure 4. Cells stably overproducing Grx2a were characterized
in terms of proliferation. Cells were stained for Mib-1. A, Mock-
transfected HeLa cells (served as control). B, tGrx2a, cells
overexpressing Grx2a but without the sequence essential for
mitochondrial translocation. C, mGrx2a, cells overexpressing the
intact mitochondrial Grx2a.
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Proliferation, as measured by Mib-1, was inversely
correlated with the expression of Grx1 and Grx2 in the
lung cancer sections examined. HeLa cells stably
transfected to overexpress the mitochondrial form of
Grx2 (Grx2a), however, showed a marked increase in
proliferation. These cells have previously also been
shown to protect against apoptosis by inhibiting the
release of cytochrome c. The discrepancy in prolifera-
tion between the tumour sections and the overproduc-
ing cells may be explained by the results with cells
overexpressing a form of Grx2a lacking the mitochon-
drial localization signal, rendering the Grx2a in these
cells cytosolic. The proliferation rate of these cells was
not affected compared with control cells. This, in turn,
was a surprising and interesting finding, showing
inconsistency between the two variants in terms of
proliferation even though they only differ in localiza-
tion. In a previous report it was suggested that there is
a transcript variant of Grx2 that is tumour specific
(Grx2c).8 This variant is also believed to be located in
the cytosol and to have exactly the same sequence as
the one overproduced in these cells. We might therefore
have a situation in these tissues where the mito-
chondrial form is suppressed to varying degrees, such
that the actual protein detected is the tumour-specific
form (Grx2c), which is not located in the mitochondria
and does not contribute to enhanced proliferation.
This is an intriguing thought, which merits further
study.
Our data clearly demonstrate a strong correlation
between differentiation and the expression of thio-
redoxin family proteins. The observations are in
keeping with previously published data on cell lines
and experimental models, and provide further evidence
for the importance of the thioredoxin family of proteins
in epithelial differentiation. Our results thus suggest a
great potential for these enzymes as tools in the
diagnosis and classification of lung tumours.
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